Literature DB >> 2982965

IgG-mediated viral clearance in experimental infection with herpes simplex virus type 1: role for neutralization and Fc-dependent functions but not C' cytolysis and C5 chemotaxis.

R R McKendall.   

Abstract

For determination of whether the Fc moiety is required for antibody effectiveness in models of herpes simplex virus type 1 (HSV-1) infection, the effects of immune IgG and F(ab')2 fragments were compared by using a passive transfer model of footpad infection. In the IgG- and the F(ab')2-treated groups illness developed in 2 (10%) of 20 and 6 (25%) of 24 mice, respectively, compared with 10 (63%) of 16 controls. IgG treatment markedly, and F(ab')2 treatment moderately, reduced footpad viral titer and viral spread to sciatic nerve and spinal cord. The marked viral clearance by IgG was not attributable to C'-dependent lysis because rapid viral clearance was observed in C5-deficient B10.D2/oSn mice. Viral latency as a consequence of acute infection occurred in 38 (63%) of 60 lumbosacral dorsal root ganglia in the control group, 5 (8%; P less than .001) of 60 in the IgG-treated group, and 26 (33%; P less than .01) of 78 in the F(ab')2-treated group.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2982965     DOI: 10.1093/infdis/151.3.464

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Direct evidence for antibody bipolar bridging on herpes simplex virus-infected cells.

Authors:  K E Van Vliet; L A De Graaf-Miltenburg; J Verhoef; J A Van Strijp
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

2.  Prevention and treatment of experimental herpes simplex virus encephalitis with human immune serum globulin.

Authors:  K S Erlich; R D Dix; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

3.  Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling.

Authors:  Mina Kalantari-Dehaghi; Sookhee Chun; Aziz Alami Chentoufi; Jozelyn Pablo; Li Liang; Gargi Dasgupta; Douglas M Molina; Algis Jasinskas; Rie Nakajima-Sasaki; Jiin Felgner; Gary Hermanson; Lbachir BenMohamed; Philip L Felgner; D Huw Davies
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

4.  Acute and latent infection of mice immunised with HSV-1 ISCOM vaccine.

Authors:  M Erturk; T J Hill; C Shimeld; R Jennings
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

5.  Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.

Authors:  L A Morrison; L Zhu; L G Thebeau
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

6.  Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing).

Authors:  H W Virgin; R Bassel-Duby; B N Fields; K L Tyler
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

7.  A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G.

Authors:  I Frank; H M Friedman
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

8.  Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms.

Authors:  Chin-Fun Chu; Michael G Meador; Christal G Young; Jane E Strasser; Nigel Bourne; Gregg N Milligan
Journal:  J Reprod Immunol       Date:  2007-10-24       Impact factor: 4.054

9.  Virus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice.

Authors:  Krystyna Mozdzanowska; Jingqi Feng; Walter Gerhard
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

10.  Antibody limits in vivo murid herpesvirus-4 replication by IgG Fc receptor-dependent functions.

Authors:  Debbie E Wright; Susanna Colaco; Camilo Colaco; Philip G Stevenson
Journal:  J Gen Virol       Date:  2009-07-22       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.